|
Collaborative Agreements (Details Textual) (USD $)
|
12 Months Ended | ||||
|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| License and Services Revenue | $ 0 | $ 7,523,438 | |||
| Research Revenue | 0 | 186,233 | |||
| Research and Development Expense, Total | 5,122,864 | 2,281,196 | |||
|
Other Companies [Member] | Collaborative Arrangement [Member]
|
|||||
| Research and Development Expense, Total | 3,400,000 | 1,100,000 | |||
|
Abbott Products, Inc. [Member] | Collaborative Arrangement [Member]
|
|||||
| Proceeds from License Fees Received | 3,000,000 | 2,000,000 | 4,000,000 | ||
| License and Services Revenue | 7,500,000 | ||||
| Research Revenue | 0 | 186,000 | |||
| Collaborative Arrangement, Termination Date | Mar. 29, 2012 | ||||
| Collaborative Arrangement, Rights and Obligations | All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1.5% royalty on net sales should Lipocine decide to use certain Solvay/Abbott formulations or a perpetual 1% royalty on net sales should Lipocine use data generated during the term of the Solvay/Abbott agreement in any regulatory filings for a product | ||||
| Collaborative Arrangement, Royalties, Maximum Amount | 1,000,000 | ||||
| Collaborative Arrangement, Royalties, Percentage of Reduction | 50.00% | ||||
|
Collaborative Product Development Agreement With Nexgen Pharma, Inc. [Member] | Research and Development Expense [Member]
|
|||||
| Reimbursement Revenue | $ 468,000 | $ 759,000 | |||